Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme

BMJ Open

Volumn 4, Issue 1, 2014, Pages

  Nygård, Mari ^a   Røysland, Kjetil ^a   Campbell, Suzanne ^a   Dillner, Joakim ^b  

^a Cancer Registry of Norway ^*  (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; FEMALE; HEALTH PROGRAM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL CARE; MIDDLE AGED; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PROSPECTIVE STUDY; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS; COMPARATIVE STUDY; EARLY DIAGNOSIS; FOLLOW UP; ISOLATION AND PURIFICATION; NORWAY; PAPILLOMAVIRIDAE; TIME; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NORWAY; PAPILLOMAVIRIDAE; PROSPECTIVE STUDIES; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84892851861     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003460     Document Type: Article

References (42)

1. Bray F, Loos AH, McCarron P, et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev 2005;14:677-86. (Pubitemid 40489214)
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50. (Pubitemid 37328947)
4. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602-10.
5. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147-72.
6. Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 2008;19:342-54.
7. Johansen BK, Skare G, Haldorsen T, et al. Masseundersøkelsen mot livmorhalskreft. Årsrapport 2008: Kreftregisteret. Institutt for populasjonsbasert kreftforskning, 2009.
8. Arbyn M, Martin-Hirsch P, Buntinx F, et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 2009;13:648-59.
9. Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002;9:86-91. (Pubitemid 34822870)
10. Nygard JF, Nygard M, Skare GB, et al. Pap smear screening in women under 30 in the Norwegian Coordinated Cervical Cancer Screening Program, with a comparison of immediate biopsy vs Pap smear triage of moderate dysplasia. Acta Cytol 2006;50:295-302. (Pubitemid 43841438)
11. Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218-31.
12. Solomon D, Nayar R. eds. The Bethesda System for reporting cervical cytology. 2nd edn. New-York: Springer-Verlag New-York, Inc., 2004.
13. Tavassoli F, Devilee P. eds Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
14. Andersen PK, Borgan O, Gill R, et al. Statistical models based on counting processes. New York: Springer-Verlag, 1993.
15. Boot: Bootstrap R (S-Plus) Functions [program]. R package version 1.3-4 version, 2012.
16. Sullivan P, Goldmann D. The promise of comparative effectiveness research. JAMA 2011;305:400-1.
17. Stoler MH, Wright TC Jr, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-75.
18. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
19. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32. (Pubitemid 46986496)
20. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.
21. Castle PE, Glass AG, Rush BB, et al. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 2012;30:3044-50.
22. Castle PE, Schiffman M, Wheeler CM, et al. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010;19:1675-81.
23. Kjaer SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-88.
24. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26 (Suppl 10):K29-41.
25. Szarewski A, Mesher D, Cadman L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 Study. J Clin Microbiol 2012;50:1867-73.
26. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5. (Pubitemid 32221899)
27. Scott DR, Hagmar B, Maddox P, et al. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 2002;96:14-20. (Pubitemid 34194315)
28. Castle PE, Fetterman B, Poitras N, et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol 2011;117:650-6.
29. Lie AK, Lømo J, Sauer T, et al. HPV DNA versus mRNA testing in triage among Norwegian women. In: 27th-IPV-Conference. Poster presentation. Berlin, 2011.
30. Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007;197:356 e1-6.
31. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
32. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72. (Pubitemid 350137476)
33. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
34. Cuzick J. Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). Cancer Prev Res (Phila) 2010;3:689-91.
35. Wahlstrom C, Iftner T, Dillner J, et al. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol 2007;79:1169-75. (Pubitemid 47015417)
36. Cuzick J, Szarewski A, Mesher D, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int J Cancer 2008;122:2294-300. (Pubitemid 351542334)
37. Insinga RP, Liaw KL, Johnson LG, et al. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-22.
38. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. (Pubitemid 36159887)
39. Screening for livmoderhalskræft-anbefalinger. København: Sundhedsstyrelsen, 2012. ISBN:978-87-7104-210-8
40. Lönnberg S, Skare G. Masseundersøkelsen mot livmorhalskreft. Årsrapport 2009-2011. Oslo: Kreftregisteret. Institutt for populasjonsbasert kreftforskning, 2013.
41. Iglehart JK. Prioritizing comparative-effectiveness research-IOM recommendations. N Engl J Med 2009;361:325-8.
42. Hakama M, Malila N, Dillner J. Randomised health services studies. Int J Cancer 2012;131:2898-902.